TP53 and neoplasm: In addition, we observed that patients receiving adjuvant gemcitabine expressing mutant p53 cells > 4% in tumor tissue had a longer DFS than patients expressing mutant p53 cells ≤ 4% (median 18.5 vs. 6 months, p = 0.0229) (Figure 3).